Description
Oncobit™ LBM is a targeted sequencing test to assess circulating tumor-derived DNA (ctDNA) isolated from the blood of melanoma patients.
Oncobit™ LBM is minimally invasive and provides a comprehensive blood-based tumor profile at baseline and disease progression by assessing cancer and therapy resistance markers. It generates a genetic characterization of the patient’s cancer in absence of a tissue biopsy as well as a personalized therapy adjustment.
Oncobit™ LBM is currently used in clinical studies and for research.
Oncobit™ LBM captures:
- mutations in 60 melanoma-relevant genes
- therapy-relevant HLA types
